ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

IOM: No Negligence In FIAU Clinical Trial That Killed Five

March 31, 1995

NCI Human Tissue Network Resources Available For Research

January 24, 1997

DCPC Board Okays Start of Low Fat High Risk Breast Cancer Study, Delays Stage 2 Trial

February 1, 1985

In Brief; Jerome Green To Head NIH Div. Of Research Grants; M.D. Anderson’s Even Hersh To Join Univ. of Arizona

December 13, 1985

Animal Diagnostic Lab concept OK’d

February 18, 1994

Centers Ask Americans for $1 Each for Research.

May 16, 2008